Search results for "biologic drug"

showing 5 items of 5 documents

Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients

2016

Adult-onset Still’s disease (AOSD) is a systemic inflammatory condition of unknown aetiology characterized by typical episodes of spiking fever, evanescent rash, arthralgia, leukocytosis and hyperferritinemia. Given the lack of data in Italian series, we promote a multicentric data collection to characterize the clinical phenotype of Italian patients with AOSD. Data from 245 subjects diagnosed with AOSD were collected by 15 centres between March and May 2013. The diagnosis was made following Yamaguchi’s criteria. Data regarding clinical manifestations, laboratory features, disease course and treatments were reported and compared with those presented in other published series of different et…

Male0301 basic medicinePediatricsAdult-onset Still's diseaseSettore MED/16 - REUMATOLOGIALeukocytosisClinical presentationArthritisComorbidityDiseaseLaboratory finding0302 clinical medicineAdrenal Cortex HormonesLeukocytosisAdult-onset Still’s diseaseBiologic drugsMedicine (all)General MedicineMiddle AgedRashRetrospective studyTreatment OutcomeItalyAdult-onset Still’s disease; Biologic drugs; Clinical presentation; Laboratory findings; Retrospective study; Rheumatology; Medicine (all)Antirheumatic AgentsFemalemedicine.symptomStill's Disease Adult-OnsetAdultLaboratory findingsmedicine.medical_specialtyAdolescentFeverNOYoung Adult03 medical and health sciencesRheumatologyInternal medicinemedicineHumansAgedRetrospective Studies030203 arthritis & rheumatologybusiness.industryAdult-onset Still’s disease; Biologic drugs; Clinical presentation; Laboratory findings; Retrospective study; RheumatologyRetrospective cohort studymedicine.diseaseNeutrophiliaRheumatologySurgery030104 developmental biologybusinessBiologic drug
researchProduct

Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group

2011

INTRODUCTION: We decided to conduct a study to investigate the presence of cytokines in the albuginea of subjects with Peyronie's disease (PD). Cytokines, as responsible for intercellular communication, maybe involved in the pathogenesis of the disease. The identification of one or more involved cytokines may, in fact, be useful in the pharmacological treatment with biologic drugs that are able to interfere with specific cytokines. MATERIALS AND METHODS: Between January 2009 and Decembre 2010 at the Clinic of Urological outpatients clinic of the Policlinico of Palermo were recruited 20 subjects with PD, mean age 62.3 years (range 51-70) and 8 subjects with congenital recurvatum penis (mean …

cytokines Induratio Penis Plastica Peyronie's disease Gene expression Tunica albuginea Biologic drugsSettore MED/24 - Urologia
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

The ocular manifestations in IBD screening (OMIS) questionnaire: pilot study on detection of ocular involvement in inflammatory bowel diseases.

2020

Purpose: To assess the usefulness of a dedicated questionnaire for patients with inflammatory bowel diseases (IBD) treated with biological drugs for the detection of ocular extraintestinal manifestations (EIMs). IBD can cause extraintestinal symptoms including ocular complaints which are frequently ignored and may be associated with significant morbidity, including blindness. Methods: We developed a questionnaire, named Ocular Manifestations in IBD Screening (OMIS) questionnaire, after agreement between gastroenterologists and ophthalmologists. The questionnaire was administered by a non-ophthalmologist physician to 96 IBD patients treated with biological drugs. Results: 35 patients (36.5%)…

Clinical teammedicine.medical_specialtygenetic structuresScreening testPilot ProjectsInflammatory bowel diseaseBiological drugsQuality of lifeInternal medicineSurveys and QuestionnairesmedicineHumansBlindnessBiologic drugs Inflammatory bowel disease Ocular extraintestinal manifestation QuestionnaireOphthalmologistsbusiness.industrySettore MED/30 - Malattie Apparato VisivoInflammatory Bowel Diseasesmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseaseseye diseasesOphthalmologyOphthalmologic examinationQuality of LifebusinessInternational ophthalmology
researchProduct